December 2020 in “Journal of Drugs in Dermatology”
The document concludes that more research is needed to confirm if blood tests for things like iron and vitamin D are helpful for hair loss from Telogen effluvium.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
The user is using a combination of hair loss treatments including finasteride, stemoxydine, oral minoxidil, RU58841, dermastamping, ketoconazole shampoo, collagen, Viviscal, and biotin, and has improved their diet. Despite these efforts, they are still experiencing hair shedding and scalp itchiness, and are considering increasing their minoxidil dosage or starting dutasteride.
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.